RTSM Reusability: What It Is, Why Most Systems Lack It, And Why It Matters

By Chuck Harris, founder and COO, Korio

In clinical operations, the struggle with Randomization and Trial Supply Management (RTSM) often stems from a fundamental misunderstanding: treating it as a static setup rather than a dynamic system for managing change. While 80% of RTSM requirements—like screening flows and dispensation rules—are essentially universal, many systems are still built as bespoke, fragile codebases. This "custom-everything" approach creates a significant risk during User Acceptance Testing (UAT) and mid-study amendments, where even minor protocol shifts can lead to functional breakdown and heavy manual rework.

The shift toward a platform-based architecture changes this trajectory. By utilizing validated, configuration-driven models instead of individual custom builds, sponsors can achieve over 90% functional reuse. This structural leverage means that institutional memory is embedded within the system rather than tied to specific individuals. When the platform is stable and predictable, timelines for enhancements shrink, and the system becomes more resilient as study complexity accumulates. Understanding the distinction between a one-off build and a reusable platform is essential for teams looking to reduce operational risk and ensure their RTSM can handle the inevitable evolution of a modern clinical trial.